Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Clinical Trial Details
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
Complete Title: A Phase 1b/2, Open-Label, Dose Escalation and Expansion Study of ADG126 in Combination with Pembrolizumab (Anti PD-1 Antibody) in Patients with Advanced/Metastatic Solid Tumors
Trial Phase: I/II
Investigator: Tina Rodriguez
This is a Phase 1b/2, open-label, dose escalation study to evaluate the safety, tolerability, PK, and immunogenicity of ADG126-pembrolizumab combination regimens in patients with advanced/metastatic solid tumors.
Keywords:
- Solid Tumors
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
Adult
I/II
Tina Rodriguez
RG1123226
NCT05405595
A Phase 1b/2, Open-Label, Dose Escalation and Expansion Study of ADG126 in Combination with Pembrolizumab (Anti PD-1 Antibody) in Patients with Advanced/Metastatic Solid Tumors
Solid Tumors